Anti-inflammatory treatment, using IL-6 blockade, has shown promising effects in smaller clinical trials in people with higher risk for CVD (for example, rheumatoid arthritis and renal failure)73,74, supporting the design of larger trials with a longer duration of follow-up. This evidence concerns the gene IL6 and kidney failure.